Abatacept for lung disease in people with common variable immunodeficiency (GLILD)
Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) IND #152820 9/2/20
This compares abatacept with a placebo to see whether abatacept can improve the lung disease (GLILD) that can occur in people with CVID.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11261089 on NIH RePORTER |
What this research studies
If you have CVID with granulomatous-lymphocytic interstitial lung disease (GLILD), this trial will randomly give participants either the drug abatacept or a placebo without telling them which for six months, followed by a six-month phase when everyone can receive abatacept. Abatacept is a biologic medicine that works by blocking T cell activation through CTLA-4 binding to CD80/CD86. The team previously saw improvement in a small group of patients and now plans a blinded, controlled approach to measure benefits and risks more clearly. The trial is led from Cincinnati Children’s Hospital and uses clinical visits and monitoring over the treatment periods.
Who could benefit from this research
Good fit: Ideal candidates are people diagnosed with common variable immunodeficiency (CVID) who have GLILD and meet the study’s eligibility requirements.
Not a fit: People with CVID who do not have GLILD, or those with active infections or other medical reasons that make abatacept unsafe, are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, abatacept could reduce lung inflammation from GLILD and improve breathing and quality of life for people with CVID.
How similar studies have performed: Small case series have reported good responses to abatacept in patients with CVID-related GLILD, but this is the first rigorous randomized, blinded trial to test it.
Where this research is happening
Cincinnati, United States
- Cincinnati Childrens Hosp Med Ctr — Cincinnati, United States (Active)
Researchers
- Principal investigator: Jordan, Michael — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Jordan, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.